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Abstract
Background: Recognition of lipopolysaccharide (LPS) is required for effective defense against invading gram-negative
bacteria. Recently, in vitro studies revealed that CD14 is required for activation of the myeloid differentiation factor (MyD)88-
dependent Toll-like receptor (TLR)4 signaling pathway by smooth (S)-LPS, but not by rough (R)-LPS. The present study
investigated the role of CD14 in induction of lung inflammation in mice by these different LPS chemotypes.
Methodology/Results: Neutrophil accumulation and tumor necrosis factor (TNF) release in bronchoalveolar lavage fluid
were determined 6 hours after intranasal treatment of wild type (WT) and CD14 knock-out (KO) mice with different doses S-
LPS or R-LPS. The contribution of CD14 to lung inflammation induced by S-LPS or R-LPS depended on the LPS dose. At low
doses, S-LPS and R-LPS induced neutrophil influx in a CD14-dependent manner. Low dose S-LPS-induced cytokine release
also depended on CD14. Strikingly, neutrophil influx and TNF release induced by high dose S-LPS or R-LPS was diminished
in the presence of CD14. Intranasal administration of sCD14 to CD14 KO mice treated with S-LPS partially reversed the
inflammatory response to the response observed in WT mice.
Conclusions: In conclusion, CD14 modulates effects of both S-LPS and R-LPS within the lung in a similar way. Except for R-
LPS-induced TNF release, S-LPS and R-LPS at low dose induced acute lung inflammation in a CD14-dependent manner,
while the inflammatory response triggered by high dose S-LPS or R-LPS was diminished by CD14.
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Introduction
Recognition of endotoxin or LPS, a major constituent of the
outer membrane of gram-negative bacteria, has been extensively
studied to clarify the mechanisms by which this component
activates the immune system [1]. Detection of LPS and initiation
of a rapid inflammatory response are required for effective defense
against invading gram-negative bacteria [2].
LPS is bound by MD-2 within the TLR4/MD-2 complex [3]
and subsequent conformational changes in TLR4 lead to
reorganization of its cytoplasmic domain, enabling the recruitment
of the adaptors MyD88 and Toll/interleukin 1 receptor domain-
containing adaptor inducing interferon beta (TRIF) [4]. These
adaptors initiate signal transduction to the nucleus leading to
production of cytokines and chemokines that regulate inflamma-
tory cells [4]. Binding of LPS to the TLR4/MD-2 complex is
facilitated by LPS binding protein (LBP) and CD14 [1]. LBP,
which is present in the bloodstream and the lung [5,6], binds to
LPS aggregates and transfers LPS monomers to CD14 [7]. CD14,
a 55-kDa glycoprotein predominantly expressed on the surface of
myeloid cells via a glycosylphosphatidyl anchor, associates with the
TLR4/MD-2 complex and transfer LPS monomers to TLR4/
MD-2 [8]. CD14 also exists in a soluble form (sCD14), which is
able to mediate LPS-activation of cells devoid of membrane CD14
expression, such as epithelial and endothelial cells [9]. However,
high concentrations of sCD14 may interfere with LPS-induced
activation of CD14-expressing cells like macrophages [10,11].
LPS synthesized by most gram-negative bacteria consists of
three modules, the lipid A moiety, a core polysaccharide and an
O-polysaccharide of variable length (consisting of 1 to 50
monosaccharide units)[12,13] and is designated smooth LPS (S-
LPS). Gram-negative bacteria that fail to add the core polysac-
charide or the O-polysaccharide chain to lipid A produce ‘rough’
LPS (R-LPS). Lipid A, the bioactive part of both S-LPS and R-
LPS, is responsible for most of the pathogenic effects in gram-
negative bacterial infections [1].
Recently, it was reported that in the absence of CD14, the
TLR4/MD-2 complex can distinguish between these LPS
chemotypes [14]. Macrophages lacking CD14 secreted equal
amounts of TNF as macrophages expressing CD14 upon
stimulation with R-LPS, but failed to secrete TNF in response to
S-LPS which was reversed by addition of sCD14 [14]. These data
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10183indicate that the TLR4/MD-2 complex requires CD14 for the
activation of MyD88-dependent signaling by S-LPS, but not by R-
LPS. Previously, we and others showed that CD14 is an essential
receptor in LPS-induced lung inflammation and pneumonia
caused by gram-negative bacteria [15–18]. The aim of the present
study was to investigate the role of CD14 in the induction of acute
lung inflammation by these different LPS chemotypes.
Results
S-LPS- and R-LPS-induced lung inflammation is
dependent on TLR4 and MyD88
Previous studies have established that the pulmonary response
to LPS totally relies on the presence of TLR4 [15,18]. Considering
that CD14 is a co-receptor within the TLR4 receptor complex, we
first investigated whether S-LPS or R-LPS administered intrana-
sally to mice also signals through TLR4. Additionally, MyD88KO
and TRIFmut mice were treated with these LPS chemotypes in
order to establish the TLR4 signaling pathways involved in this
inflammation model. Thus, WT, TLR4KO, MyD88KO and
TRIFmut mice were treated with 10 mg of S-LPS or R-LPS and
the influx of polymorphonuclear cells (PMNs) into BALF, as well
as the BALF concentrations of TNF (a cytokine primarily
produced by macrophages)[19,20] and LIX (a chemokine
exclusively produced by respiratory epithelial cells)[20] was
measured as read outs for the pulmonary response to local LPS
instillation. BALF was obtained 6 hours after LPS administration,
since this time point is representative for both PMN influx and
local cytokine/chemokine release [6,15,18,20]. Compared to WT
mice, S-LPS- or R-LPS-induced PMN influx was equally and
strongly reduced in TLR4KO and MyD88KO mice (P,0.001,
Fig. 1A,B). Similarly, BALF TNF and LIX concentrations were
markedly and equally reduced in TLR4KO and MyD88KO upon
intrapulmonary delivery of S-LPS or R-LPS (P,0.01, Fig. 1 C–
F). In TRIFmut mice, S-LPS- or R-LPS-induced BALF TNF
levels were also strongly reduced (P,0.001), but PMN influx and
BALF LIX levels were not or modestly lowered (Fig. 1A–F). These
results indicate that the pulmonary response triggered by either S-
LPS or R-LPS requires TLR4 and predominantly MyD88-
dependent signaling.
CD14 deficiency results in enhanced TNF release upon
pulmonary instillation of S-LPS and R-LPS
To determine the role of CD14 in lung inflammation induced
by S-LPS or R-LPS, WT and CD14KO mice were treated
intranasally with 10 mg of either form of LPS and analyzed
6 hours later. Surprisingly, S-LPS induced a significantly higher
PMN influx in CD14KO mice as compared to WT mice (P,0.01,
Fig. 2A). In addition, 10 mg of S-LPS also induced higher
concentrations of TNF (P,0.01) in BALF of CD14KO mice
(Fig. 2D). R-LPS tended to elicit increased influx of PMNs in
BALF of CD14KO mice (not significant, Fig. 3A), but did induce
increased release of TNF (P,0.01, Fig. 3D). At this LPS dose,
BALF LIX levels were not influenced by CD14 deficiency. Thus,
inflammatory responses induced by either S-LPS or R-LPS within
the bronchoalveolar space did not depend on CD14; in contrast,
some responses were even enhanced in CD14KO mice, suggesting
an inhibitory role of this receptor.
CD14 deficiency attenuates lung inflammation induced
by low doses of S-LPS or R-LPS
To determine whether the partially enhanced lung inflamma-
tion was dependent on the dose of LPS, WT and CD14KO mice
were treated intranasally with lower amounts of S-LPS or R-LPS
and analysed 6 hours later. CD14KO mice treated with 0.1 mgo f
LPS showed a reduced influx of PMNs in response to S-LPS or R-
LPS (both P,0.001 versus WT mice, Fig. 2C and 3C). In response
to 1 mg of either S-LPS or R-LPS, CD14KO mice tended to have
an impaired PMN influx (not significant versus WT mice; Fig. 2B
and 3B). This was accompanied by significantly reduced BALF
TNF levels in S-LPS-treated CD14KO mice (P,0.01, Fig. 2E, F),
but increased TNF levels in R-LPS-treated CD14KO mice
(P,0.001, Fig. 3E). The local release of LIX was facilitated by
the presence of CD14 at lower S-LPS and R-LPS doses, i.e.
CD14KO mice treated with 0.1 mg of LPS displayed lower LIX
BALF levels than WT mice (P,0.05, Fig 2I and 3I). Together,
these findings reveal that CD14 in the lung either does not
influence or diminishes inflammatory responses induced by high
concentrations of S-LPS or R-LPS, but augments inflammation
triggered by low concentrations of S-LPS or R-LPS. Moreover,
CD14 does not facilitate local release of TNF induced by
intrapulmonary R-LPS at any dose tested.
Effects of sCD14 on S-LPS induced lung inflammation
The data presented above provided clear evidence for a bimodal
role of CD14 in the pulmonary responses induced by S-LPS. Since
sCD14 can modulate LPS-induced responses [7], we were
interested in establishing whether sCD14 can compensate for
CD14 gene deficiency with regard to inhibition and enhancement
of S-LPS effects at different doses. First, we measured sCD14
concentrations in BALF of WT mice 6 hours after instillation of
different doses of S-LPS (10, 1 and 0.1 mg). As shown in figure 4, S-
LPS elicited a dose-dependent rise in BALF sCD14 levels. To
exclude the possibility that the increase in alveolar sCD14 levels
resultedfromleakage ofserumproteins,totalproteinconcentrations
in BALF of LPS-treated WT mice were assessed. No differences in
total BALF protein levels were observed in these mice 6 hours after
treatment with 10, 1 or 0.1 mg S-LPS (data not shown). Next, we
administered CD14KO mice with sCD14 (10 mg) intranasally
together with S-LPS at either 10 mg( i.e. a dose at which CD14
inhibits S-LPS induced lung inflammation, Fig. 2) or 0.1 mg( i.e. a
dose at which CD14 enhances S-LPS induced lung inflammation,
Fig. 2). In these experiments the phenotype of CD14KO mice after
intranasal administration of S-LPS at a high or low dose was
reproduced (Fig. 5). Importantly, sCD14 treatment partially
reversed the phenotype of CD14KO mice at both S-LPS doses.
Specifically, whereas sCD14 did not impact on the enhanced PMN
influx in CD14KO mice upon instillation of S-LPS at 10 mg
(Fig. 5A), sCD14 reduced the exaggerated TNF release in CD14
KO mice to levels found in WT mice (P,0.01 for the difference
with CD14 KO, Fig. 5C). At this LPS dose, neither sCD14
administration nor CD14 deficiency influenced LIX release. In
addition, whereas sCD14 modestly but significantly increased the
reduced PMN influx in CD14 KO mice upon instillation of S-LPS
at 0.1 mg( P ,0.01 for the difference with CD14 KO mice, Fig. 5B),
this treatment did not influencethe reduced TNF release into BALF
in CD14 KO mice at this LPS dose (Fig. 5D). Remarkably,
however, sCD14 administration strongly increased the release of
LIX in CD14KO mice exposed to 0.1 mg S-LPS (P,0.001 versus
CD14KO mice, Fig. 5F). Taken together, these results suggest that
sCD14 may inhibit or facilitate S-LPSeffects inthe bronchoalveolar
space depending on the LPS dose used.
Discussion
CD14 was discovered as LPS receptor nearly two decades ago
[1], but many aspects of its role in LPS-induced responses still
Lung CD14 & LPS Chemotypes
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has indicated that whereas the TLR4/MD-2 complex requires
CD14 for the activation of MyD88-dependent signaling by S-LPS
[14], the main form of LPS produced by most gram-negative
bacteria, it does not require CD14 for activation by R-LPS.
Elaborating on this notion, previous findings of us and others that
CD14 is essential in LPS-induced lung inflammation [15–18] and
pneumonia caused by Acinetobacter baumannii [15] are explained by
the predominance of the smooth form of LPS in the inocula. Of
note, however, in vivo experiments have revealed that the lethal
effects of both S-LPS and R-LPS depend on CD14 [14]. Together,
these findings prompted us to re-evaluate the role of pulmonary
CD14 in vivo in acute lung inflammation induced by different LPS
chemotypes. Using CD14KO mice treated intranasally with
various doses of S-LPS or R-LPS, we demonstrate here that
CD14 plays a bimodal role in the induction of PMN influx and
local TNF release in response to intrapulmonary delivery of S-
LPS, inhibiting S-LPS effects at high doses while facilitating the
effects at low doses. Moreover, we show that sCD14 can partially
reproduce these differential roles of CD14. In addition, our results
reveal that CD14 modulates the effects of R-LPS and S-LPS
within the lung in vivo in a similar way, with the important
exception that this receptor did not facilitate TNF release at any
R-LPS dose.
In the present study, we found at low doses that R-LPS (but not
S-LPS) induced TNF secretion in the lung in a CD14-independent
manner, whereas PMN recruitment into the lung was induced by
these LPS chemotypes in a CD14-dependent manner. The
requirement of CD14 in S-LPS-induced inflammatory responses
is in line with previous in vitro and in vivo studies with cytokine
Figure 1. S-LPS- and R-LPS-induced acute lung inflammation is dependent on TLR4 and MyD88 and partially TRIF dependent. Mice
(n=8–9 per group) were inoculated intranasally with 10 mg of S-LPS (left panel) or R-LPS (right panel) and analysed 6 hours later for lung PMN influx
(A, B), and TNF (C, D) and LIX (E, F) release in BALF. Data are mean 6 SEM. **, P,0.01, *** P,0001 versus WT mice.
doi:10.1371/journal.pone.0010183.g001
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CD14 to R-LPS- induced cytokine release are inconsistent: CD14
has been reported to be irrelevant for R-LPS-induced TNF
production [14], whereas other investigations found that CD14
augmented R-LPS-induced cytokine secretion by macrophages
[12,21] as well as plasma TNF levels triggered by intravenous R-
LPS [12]. Our present results suggest that CD14 facilitates some
but not all R-LPS-induced responses in the bronchoalveolar space.
The contrasting influence of CD14 on TNF and PMN influx in
the lung may result from differential CD14 dependency of lung
cells responding to low dose R-LPS. Alveolar macrophages, which
express both CD14 and TLR4 [22] and are major producers of
TNF, may not require CD14 to respond to low dose R-LPS as
previously found with peritoneal macrophages [14]. Lung
epithelial cells, which constitutively express TLR4 but lack
CD14 [23] and which are essential for the influx of PMN upon
intrapulmonary instillation of LPS [24], may require (s)CD14 to
respond to low doses of R-LPS [9,12]. In accordance, CD14KO
mice displayed lower BALF concentrations of LIX, a chemokine
exclusively produced by respiratory epithelial cells [20], upon
intranasal instillation of R-LPS at low doses.
At high doses, neither S-LPS nor R-LPS required CD14 to
induce PMN influx or TNF and LIX secretion in BALF, which is
in line with the results of others obtained with LPS stimulated
macrophages [21] or a mouse model of LPS-induced lung
inflammation [18]. Strikingly, in response to high dose LPS,
PMN recruitment and TNF release in the lung were exaggerated
in CD14KO mice relative to WT mice. Although our study does
not elucidate the mechanism underlying this intriguing finding,
we did demonstrate that high dose S-LPS (Fig. 4) and R-LPS
(data not shown) induce the release of sCD14 in WT mice, which
may down-regulate further LPS-induced inflammatory processes.
Studies by Haziot et al. [10] and Stelter et al. [11] revealed that
high concentrations of sCD14 can inhibit LPS-induced secretion
of TNF by macrophages, which may result from transfer of LPS
to lipoproteins and subsequent removal [7]. This notion is
partially supported by our experiments in which sCD14 was
administered to CD14KO mice, i.e. intranasal instillation of
exogenous sCD14 together with high dose S-LPS to CD14KO
mice resulted in a significant reduction of TNF release in the
lung, but this treatment did not affect PMN infiltration into
BALF. These findings suggest that sCD14 released in response to
high dose LPS regulates LPS-responsiveness of cells secreting
TNF, but not the cells responsible for the attraction of PMNs.
This possibility is supported by the lack of an effect of (s)CD14 on
LIX release after high dose LPS administration, considering that
respiratory epithelial cells are important for both PMN influx and
LIX secretion [20,24]. Alternatively, high dose LPS in a CD14-
dependent manner may trigger the release of LBP, which like
sCD14 down-regulates LPS-induced inflammatory processes [7].
Previously, we found that lung inflammation induced by high
dose LPS was enhanced in LBPKO mice [6], closely resembling
the present findings in CD14KO mice. LBP levels in the lungs of
WT and CD14KO mice treated with high dose LPS, however,
did not differ (data not shown). Therefore, further investigations
are required to determine the mechanism underlying the reduced
inflammation in WT mice treated with high dose LPS as
compared to CD14KO mice.
TLR4 induces two independent signaling pathways that are
regulated by MyD88 and TRIF [4]. Recently, it was established
Figure 2. Pulmonary CD14 diminishes lung inflammation by high dose S-LPS, but enhances lung inflammation by low dose S-LPS.
Mice (n=7–9) were treated intranasally with 10 mg S-LPS (left panel), 1 mg S-LPS (middle panel) or 0.1 mg S-LPS (right panel). Six hours later BALF was
isolated and analysed for PMN counts (A–C), TNF levels (D–F) and LIX levels (G–I). Data are mean 6 SEM. **, P,0.01; ***, P,0001 versus WT mice.
doi:10.1371/journal.pone.0010183.g002
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pathway by either S-LPS or R-LPS [14]. TRIF-dependent
signaling is essential for the expression of the majority of LPS-
induced genes in macrophages [25], including IFN-a/b [26]. In
line with others [27], we found in the present study that TRIF
was required for LPS-induced secretion of TNF in the lung, but
dispensable for the infiltrationo ft h el u n gb yP M N .O fi n t e r e s t ,
the release of LIX into BALF, which is considered to occur
exclusively by respiratory epithelial cells [20], was not (R-LPS)
or only modestly (S-LPS) influenced by the presence of TRIF.
Considering that PMN influx in response to intrapulmonary
administration of LPS largely depends on activation of the
respiratory epithelium [24], these data together suggest that
TRIF deficiency does not impact on the responsiveness of lung
epithelial cells toward LPS in vivo.
A limitation of the present study is that the effect of LPS on
cytokine release and neutrophil influx in the lung was studied at
one time point only. Previously, we performed a kinetic analysis of
LPS dosage effects in wild-type and LBP-deficient mice and found
that both cytokine release and neutrophil influx in the lung peaked
at 6 hours after LPS instillation, with the exception that neutrophil
infiltration triggered by high dose LPS further increased at a later
time point (22 h) [6]. Similar kinetics of cytokine release and
neutrophil infiltration of the lung (with maximum responses at the
2 and 8 hour time point, respectively) after intranasal LPS
instillation in wild-type and CD14-deficient mice were found by
others [18]. On the basis of these results we have chosen to
investigate the effect of LPS on both cytokine release and
neutrophil influx in the lung only at the 6 hour time point.
Further studies are required to determine the detailed kinetics of
LPS dosage effects in wild-type and CD14-deficient mice.
In summary, our study shows that the effects of both S-LPS and
R-LPS in the lung are mediated by pulmonary CD14. Acute lung
inflammation induced by low doses S-LPS or R-LPS was
dependent on CD14, whereas inflammatory responses induced
by high LPS doses were diminished in the presence of CD14.
Further studies are required to disentangle the dual role of CD14
in LPS-induced acute lung inflammation.
Figure 4. S-LPS induces sCD14 release in the lung in a dose
dependent manner. sCD14 was measured in BALF obtained from WT
mice 6 hours after intranasal administration of different doses (10–
0.1 mg) of S-LPS. Eight to nine mice were used per group. Data are mean
6 SEM. Dotted line represents the mean value of sCD14 in BALF of
naive mice.
doi:10.1371/journal.pone.0010183.g004
Figure 3. Pulmonary CD14 partially diminishes lung inflammation by high dose R-LPS, but enhances lung inflammation by low
dose R-LPS. Mice (n=6–9) were treated intranasally with 10 mg R-LPS (left panel), 1 mg R-LPS (middle panel) or 0.1 mg R-LPS (right panel). Six hours
after LPS administration, BALF was isolated and analysed for PMN counts (A–C), TNF levels (D–F) and LIX levels (G–I). Data are mean 6 SEM. *, P,0.05;
**, P,0.01; ***, P,0001 versus WT mice.
doi:10.1371/journal.pone.0010183.g003
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Ethics statement
The Animal Care and Use Committee of the University of
Amsterdam approved all animal experiments. Experiments have
been conducted according to national guidelines.
Mice
Pathogen-free 10–12 week old WT mice (Harlan Sprague
Dawley, Horst, Netherlands), TLR4KO, MyD88KO, CD14KO
mice (Jackson Laboratories, Bar Harbor, ME) and TRIF mutant
(TRIFmut) mice (all on C57BL/6 genetic background) were used
in this study. Knock-out and mutant mice were generated as
described previously [26,28–30].
LPS-induced lung inflammation
Lung inflammation was induced in mice as described previously
[6]. Salmonella abortus equi S-LPS or Salmonella minnesota Re595 R-
LPS (Alexis, San Diego, CA) was diluted at different doses (0.1 mg,
1 mgo r1 0 mg) in 50 ml sterile pyrogen-free 0.9% saline and
instilled intranasally during anesthesia by inhalation of isoflurane
(Abbott Laboratories, Kent, UK). Six hours after LPS inoculation,
mice were anesthetized with ketamin (Eurovet, Bladel, Nether-
lands) and medetomidin (Pfizer, Capelle, Netherlands) and
Figure 5. sCD14 exerts bimodal effects in acute lung inflammation depending on the dose of S-LPS. WT and CD14KO mice were
treated intranasally with 10 mg S-LPS (left panel) or 0.1 mg S-LPS (right panel) and 10 mg sCD14 was administered simultaneously with S-LPS to
groups of CD14KO mice. Six hours after LPS (and sCD14) administration, BALF was isolated and analyzed for PMN counts (A, B), TNF levels (C,
D) and LIX levels (ER, F). Eight to nine mice were used per group. Data are are mean 6 SEM. *, P,0.05; **, P,0.01; ***, P,0001 versus WT
mice; ##,P ,0.01; ###,P ,0.001 versus CD14KO mice.
doi:10.1371/journal.pone.0010183.g005
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experiments, CD14KO mice were treated intranasally with
sCD14 (1 or 10 mg) and S-LPS (0.1 or 10 mg) simultaneously.
Bronchoalveolar lavage
Bilateral bronchoalveolar lavage (BAL) with two 0.5-ml aliquots
of sterile saline was performed as described previously [6]. Total
cell numbers were counted using a Z2 Coulter counter (Beckman-
Coulter, Miami, FL). BAL fluid (BALF) differential cell counts
were performed on Giemsa-stained cytospin preparations. BALF
supernatant was stored at 220uC until analysis.
Mouse recombinant sCD14
Mouse recombinant sCD14 (AA16-336) lacking N- and C-
terminal signal peptides was produced by cultured Drosophila S2
cells according to previously described procedures [31]. Briefly,
sCD14 was amplified from lungs of WT C57BL6 mice using
specific primers: 59- AAAAAAAACCATGGTCTCCCGCCC-
CACCAGAG -39 and 59- AAAAAAAATCTAGAGTTAAACT-
TCTCCGAGTG -39 and high fidelity Taq polymerase (Invitro-
gen, Carlsbad, CA), and subcloned into pMTBiP/V5-HisA
(Invitrogen). Transfected S2 cells were induced with 500 mM
copper sulfate for 4 days to secrete sCD14 in serum-free medium.
Mouse recombinant sCD14 was purified from the culture
supernatant using a HIS-trap nickel column (GE Healthcare
Biosciences, Uppsala, Sweden). The purified 48-kDa protein
enhanced LPS-induced TNF secretion by alveolar macrophages in
vitro (data not shown). The endotoxin level was 0.8 EU/mg sCD14
as determined by limulus amoebocyte lysate assay (Lonza,
Verviers, Belgium).
Assays
BALF TNF, LPS-induced CXC chemokine (LIX, CXCL5) and
sCD14 levels were measured using ELISA (TNF, LIX: R&D
Systems, Minneapolis, MN; sCD14: Biometec, Greifswald,
Germany). The detection limit was 15.6 pg/ml for TNF and
LIX, and 3.13 ng/ml for sCD14.
Statistical analysis
Data were analyzed using GraphPad Prism software version
4.03 (GraphPad Prism, San Diego, CA). The Mann-Whitney U
test was used for calculating differences between two groups. All
data are given as means 6 SEM. P-values less than 0.05 were
considered statistically significant.
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